Adenocarcinoma

From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. One case of … (full text at CIViC)

PMID 31375766 · Solomon et al., 2020 · Open in CIViC

A 45-year-old non-smoking female patient was diagnosed with a stage IV lung adenocarcinoma and magnetic resonance imaging showed multiple brain metastases. Targeted NGS analysis on the pleural biopsy … (full text at CIViC)

PMID 36419889 · Lazzari et al., 2022 · Open in CIViC

Of 351 primary thyroid carcinoma patients assessed by targeted gene rearrangement next-generation assay, 11 cases (3.1%) had NTRK rearrangement. Only one case of EML4::NTRK3 fusion (e2,e13) with an in… (full text at CIViC)

PMID 32457407 · Chu et al., 2020 · Open in CIViC

Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice tran… (full text at CIViC)

PMID 22802530 · Utermark et al., 2012 · Open in CIViC

LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider ra… (full text at CIViC)

PMID 26822398 · Harbeck et al., 2016 · Open in CIViC

A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated wi… (full text at CIViC)

PMID 22418700 · Lin et al., 2012 · Open in CIViC

With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB recepto… (full text at CIViC)

PMID 22418700 · Lin et al., 2012 · Open in CIViC

This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment. 121 patients with HER2 overexpressing breast cancer with CNS recu… (full text at CIViC)

PMID 26596672 · Cortés et al., 2015 · Open in CIViC

Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB… (full text at CIViC)

PMID 26668065 · Huguet et al., 2016 · Open in CIViC

In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or t… (full text at CIViC)

PMID 25537159 · Rimawi et al., 2015 · Open in CIViC

Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers. The irreversible TKI afati… (full text at CIViC)

PMID 25370464 · Ring et al., 2015 · Open in CIViC

155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to E… (full text at CIViC)

PMID 23470965 · Yu et al., 2013 · Open in CIViC

TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer. Primary endpoint was Overall Survival (… (full text at CIViC)

PMID 24868024 · Satoh et al., 2014 · Open in CIViC

This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment. Patients were given capecitabine (n=161)… (full text at CIViC)

PMID 17192538 · Geyer et al., 2006 · Open in CIViC

In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 po… (full text at CIViC)

PMID 22493419 · Guarneri et al., 2012 · Open in CIViC

This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells. In th… (full text at CIViC)

PMID 20124187 · Blackwell et al., 2010 · Open in CIViC

In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than s… (full text at CIViC)

PMID 22257673 · Baselga et al., 2012 · Open in CIViC

Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab (n=63) and trastuzumab-naive (n=64) cohorts in a Phase II trial. As for the primary endpoint, the 16-week… (full text at CIViC)

PMID 20142587 · Burstein et al., 2010 · Open in CIViC

A panel of HER2 positive breast cancer cell lines (n=12) displayed greater sensitivity to Neratinib (HKI-272) compared to triple negative breast cancer cell lines (n=15, p=.0002) and luminal breast ca… (full text at CIViC)

PMID 24009064 · Canonici et al., 2013 · Open in CIViC

Two HER2 positive breast cancer cells lines were 480-times more sensitive to Neratinib (HKI-272) compared to a HER2 negative breast cancer cell line (MDA-MB-435) as indicated by decreased proliferatio… (full text at CIViC)

PMID 15173008 · Rabindran et al., 2004 · Open in CIViC

A phase III clinical trial (NALA, NCT01808573) with a randomized parallel design of 621 patients evaluated the combination therapy of Neratinib plus capecitabine (N+C) (307 pts.) vs. Lapatinib plus ca… (full text at CIViC)

Open in CIViC

A Phase II clinical trial (NCT00741260 ) assessed the safety and efficacy of Neratinib plus capecitabine in the treatment of HER2 positive breast cancer patients. Of the 72 patients in this study, 65 … (full text at CIViC)

PMID 25287822 · Saura et al., 2014 · Open in CIViC

In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assesse… (full text at CIViC)

PMID 26874901 · Chan et al., 2016 · Open in CIViC

In this randomized, double-blind, placebo-controlled, Phase III trial, 264 patients were enrolled with histologically or cytologically confirmed diagnoses of previously untreated, locally advanced, un… (full text at CIViC)

PMID 34912120 · Janjigian et al., 2021 · Open in CIViC

CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer. Patients were HER2-positive by IHC3+ or FIS… (full text at CIViC)

PMID 25693012 · Swain et al., 2015 · Open in CIViC

In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (1… (full text at CIViC)

PMID 22149875 · Baselga et al., 2012 · Open in CIViC

The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diass… (full text at CIViC)

PMID 22802530 · Utermark et al., 2012 · Open in CIViC

Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductio… (full text at CIViC)

PMID 22802530 · Utermark et al., 2012 · Open in CIViC

HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting. Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having… (full text at CIViC)

PMID 16236737 · Piccart-Gebhart et al., 2005 · Open in CIViC

ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and plati… (full text at CIViC)

PMID 20728210 · Bang et al., 2010 · Open in CIViC

In this open-label, randomized, phase II trial, 187 patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma that had progressed while they were receiving at least two pre… (full text at CIViC)

PMID 32469182 · Shitara et al., 2020 · Open in CIViC

A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration … (full text at CIViC)

PMID 11248153 · Slamon et al., 2001 · Open in CIViC

A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progres… (full text at CIViC)

PMID 15911866 · Marty et al., 2005 · Open in CIViC

ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been co… (full text at CIViC)

PMID 20728210 · Bang et al., 2010 · Open in CIViC

HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer. HER2 overexpression in USPC is… (full text at CIViC)

PMID 18555254 · Santin et al., 2008 · Open in CIViC

A 71-year old male with metastatic extramammary Paget’s disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable di… (full text at CIViC)

PMID 25692060 · Barth et al., 2015 · Open in CIViC

In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab. Patients had 12 weeks or … (full text at CIViC)

PMID 19289619 · von Minckwitz et al., 2009 · Open in CIViC

Ovarian mucinous carcinoma responds poorly to paclitaxel and carboplatin, prompting interest in targeted therapy, and it resembles gastro-oesophageal adenocarcinoma, a tumour type in which HER2 (ERBB2… (full text at CIViC)

PMID 20003286 · McAlpine et al., 2009 · Open in CIViC

In this randomized, phase II trial, 61 patients with primary stage III or IV or recurrent HER2/neu-positive uterine serous carcinoma. Participants were randomly assigned to receive carboplatin-paclita… (full text at CIViC)

PMID 29584549 · Fader et al., 2018 · Open in CIViC

In this phase 3, open-label, randomized controlled trial, 594 patients (584 in the primary analysis) with HER2-positive amplification or overexpression gastric or gastroesophageal junction adenocarcin… (full text at CIViC)

PMID 20728210 · Bang et al., 2010 · Open in CIViC

The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated. Patients were required to have prior exposure to trastuzumab and la… (full text at CIViC)

PMID 24793816 · Krop et al., 2014 · Open in CIViC